Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.42
VRTX's Cash to Debt is ranked higher than
58% of the 1484 Companies
in the Global Biotechnology industry.

( Industry Median: 48.31 vs. VRTX: 1.42 )
VRTX' s 10-Year Cash to Debt Range
Min: 0.92   Max: 26.61
Current: 1.42

0.92
26.61
Equity to Asset 0.45
VRTX's Equity to Asset is ranked higher than
60% of the 1112 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. VRTX: 0.45 )
VRTX' s 10-Year Equity to Asset Range
Min: -0.02   Max: 0.95
Current: 0.45

-0.02
0.95
F-Score: 3
Z-Score: 12.28
M-Score: -1.70
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -108.02
VRTX's Operating margin (%) is ranked higher than
70% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -82.48 vs. VRTX: -108.02 )
VRTX' s 10-Year Operating margin (%) Range
Min: -602.63   Max: 8.07
Current: -108.02

-602.63
8.07
Net-margin (%) -117.36
VRTX's Net-margin (%) is ranked higher than
69% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. VRTX: -117.36 )
VRTX' s 10-Year Net-margin (%) Range
Min: -630.27   Max: 2.1
Current: -117.36

-630.27
2.1
ROE (%) -62.80
VRTX's ROE (%) is ranked higher than
62% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: -28.35 vs. VRTX: -62.80 )
VRTX' s 10-Year ROE (%) Range
Min: -180.27   Max: 4.58
Current: -62.8

-180.27
4.58
ROA (%) -31.40
VRTX's ROA (%) is ranked higher than
69% of the 1489 Companies
in the Global Biotechnology industry.

( Industry Median: -22.44 vs. VRTX: -31.40 )
VRTX' s 10-Year ROA (%) Range
Min: -58.14   Max: 1.51
Current: -31.4

-58.14
1.51
ROC (Joel Greenblatt) (%) -90.05
VRTX's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 1448 Companies
in the Global Biotechnology industry.

( Industry Median: -352.58 vs. VRTX: -90.05 )
VRTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1034.2   Max: 110.77
Current: -90.05

-1034.2
110.77
Revenue Growth (3Y)(%) -28.50
VRTX's Revenue Growth (3Y)(%) is ranked higher than
63% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. VRTX: -28.50 )
VRTX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -32.4   Max: 130.2
Current: -28.5

-32.4
130.2
» VRTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

VRTX Guru Trades in Q2 2014

Paul Tudor Jones 2,178 sh (New)
Ken Fisher 6,753 sh (New)
Vanguard Health Care Fund 11,807,500 sh (+1.54%)
Steven Cohen 934,700 sh (unchged)
Jim Simons Sold Out
John Burbank Sold Out
George Soros Sold Out
Pioneer Investments 850,152 sh (-28.91%)
» More
Q3 2014

VRTX Guru Trades in Q3 2014

Stanley Druckenmiller 146,600 sh (New)
Paul Tudor Jones 7,726 sh (+254.73%)
Pioneer Investments 661,813 sh (unchged)
Vanguard Health Care Fund 11,807,500 sh (unchged)
Ken Fisher 4,593 sh (-31.99%)
Steven Cohen 443,300 sh (-52.57%)
» More
Q4 2014

VRTX Guru Trades in Q4 2014

Andreas Halvorsen 764,200 sh (New)
Stanley Druckenmiller Sold Out
Pioneer Investments 647,257 sh (-2.20%)
Ken Fisher 4,378 sh (-4.68%)
Paul Tudor Jones 6,589 sh (-14.72%)
Vanguard Health Care Fund 9,808,860 sh (-16.93%)
Steven Cohen 16,500 sh (-96.28%)
» More
Q1 2015

VRTX Guru Trades in Q1 2015

Jim Simons 159,317 sh (New)
George Soros 56,912 sh (New)
Lee Ainslie 524,867 sh (New)
Louis Moore Bacon 97,500 sh (New)
Andreas Halvorsen 1,770,150 sh (+131.63%)
Steven Cohen 29,200 sh (+76.97%)
Pioneer Investments 794,247 sh (+22.71%)
Ken Fisher 4,386 sh (+0.18%)
Paul Tudor Jones Sold Out
Vanguard Health Care Fund 9,533,911 sh (-2.80%)
» More
» Details

Insider Trades

Latest Guru Trades with VRTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 28.90
VRTX's Forward P/E is ranked higher than
87% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VRTX: 28.90 )
N/A
P/B 31.40
VRTX's P/B is ranked lower than
60% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. VRTX: 31.40 )
VRTX' s 10-Year P/B Range
Min: 5.79   Max: 37
Current: 31.4

5.79
37
P/S 49.40
VRTX's P/S is ranked higher than
51% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 40.50 vs. VRTX: 49.40 )
VRTX' s 10-Year P/S Range
Min: 4.47   Max: 80.48
Current: 49.4

4.47
80.48
EV-to-EBIT -47.31
VRTX's EV-to-EBIT is ranked higher than
75% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VRTX: -47.31 )
VRTX' s 10-Year EV-to-EBIT Range
Min: -49.5   Max: 4164.9
Current: -47.31

-49.5
4164.9
Current Ratio 4.49
VRTX's Current Ratio is ranked higher than
73% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. VRTX: 4.49 )
VRTX' s 10-Year Current Ratio Range
Min: 1.73   Max: 30.95
Current: 4.49

1.73
30.95
Quick Ratio 4.38
VRTX's Quick Ratio is ranked higher than
74% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. VRTX: 4.38 )
VRTX' s 10-Year Quick Ratio Range
Min: 1.62   Max: 30.95
Current: 4.38

1.62
30.95
Days Inventory 132.49
VRTX's Days Inventory is ranked higher than
87% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VRTX: 132.49 )
VRTX' s 10-Year Days Inventory Range
Min: 62.49   Max: 254.87
Current: 132.49

62.49
254.87
Days Sales Outstanding 48.83
VRTX's Days Sales Outstanding is ranked higher than
88% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. VRTX: 48.83 )
VRTX' s 10-Year Days Sales Outstanding Range
Min: 25.75   Max: 106.15
Current: 48.83

25.75
106.15

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 431.30
VRTX's Price/Net Current Asset Value is ranked higher than
50% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 46.00 vs. VRTX: 431.30 )
VRTX' s 10-Year Price/Net Current Asset Value Range
Min: 2.19   Max: 1835.5
Current: 431.3

2.19
1835.5
Price/Tangible Book 33.40
VRTX's Price/Tangible Book is ranked lower than
61% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 10.40 vs. VRTX: 33.40 )
VRTX' s 10-Year Price/Tangible Book Range
Min: 2.9   Max: 75.48
Current: 33.4

2.9
75.48
Price/Median PS Value 2.70
VRTX's Price/Median PS Value is ranked higher than
63% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 3.00 vs. VRTX: 2.70 )
VRTX' s 10-Year Price/Median PS Value Range
Min: 0.28   Max: 4.23
Current: 2.7

0.28
4.23
Earnings Yield (Greenblatt) -2.10
VRTX's Earnings Yield (Greenblatt) is ranked higher than
78% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. VRTX: -2.10 )
VRTX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -2.1   Max: 5.3
Current: -2.1

-2.1
5.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:VX1.Germany, VRTX.Mexico,
Vertex Pharmaceuticals Inc was incorporated in 1989. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. It is focused on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and early-stage development programs. The Company has marketed KALYDECO (ivacaftor) since it was approved in 2012 for the treatment of certain patients with CF and is seeking approval to market lumacaftor in combination with ivacaftor in order to increase the number of patients with CF who would be eligible for treatment with the Company's drugs. It is engaged in a number of other research and early-stage development programs, including programs in the areas of oncology and neurology. The Company's two products are INCIVE (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus, or HCV, infection; and KALYDEC (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis, or CF, who genetic mutation in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene, which is referred to as the G551D mutation. INCIVEK is approved in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus, or HCV, infection. As the Company markets and sells its approved products and advances its drug candidates through clinical development toward commercialization, it continues to build and maintain its supply chain and quality assurance resources. It faces competition based on the safety and efficacy of its products and drug candidates, the timing and scope of regulatory approvals, the availability and cost of supply, marketing and sales capabilities, reimbursement coverage, price, patent protection and other factors. Its registered trademarks include Vertex, KALYDECO and INCIVEK. The research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, safety monitoring, record keeping, promotion, advertising, distribution and marketing of its products and drug candidates are subject to extensive regulation by United States and foreign governmental authorities.
» More Articles for VRTX

Headlines

Articles On GuruFocus.com
Lee Ainslie Adds 90 New Stocks to His Portfolio Within the First Quarter May 20 2015 
Analysts Confident That Vertex Pharmaceuticals' CF Drug Will Receive FDA Approval May 13 2015 
Fate Of Cystic Fibrosis Drug By Vertex Is Now Dependent On FDA Approval May 13 2015 
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
Weekly CFO Sells Highlight: Texas Instruments Inc, Royal Caribbean Cruises Ltd, Vertex Pharmaceutica Nov 09 2014 
Weekly CFO Sells Highllight: Facebook Inc, Vertex Pharmaceuticals Inc, Nike Inc. Oct 05 2014 
Vanguard Health Care Fund Buys Vertex Pharmaceuticals, Zoetis Inc, , Sells Cerner Corporation, AbbVi Aug 02 2013 
Weekly Guru Bargains Highlights: MBI, VRTX, GRPN, PBI, PC Dec 16 2012 
WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 21 2012 

More From Other Websites
10 S&P 500 Companies to Have the Most Revenue Growth in 2015 May 20 2015
How to play weak Q2 earnings season: Analysts May 18 2015
New England Journal of Medicine Publishes Data from Two Phase 3 Studies of ORKAMBITM... May 17 2015
What You Need To Know In Biotech: An ASCO Disappointment, Big Money In Brains And A New CF Drug May 16 2015
Vertex Could Give Investors Vertigo May 13 2015
Vertex to Present at the UBS Healthcare Conference on May 19 May 13 2015
Vertex to Present at the UBS Healthcare Conference on May 19 May 13 2015
Gilead: No Big Deals May 13 2015
Vertex Pharmaceuticals (VRTX) Stock Climbs Following FDA Advisory Panel Aprroval May 13 2015
Analyst: Patients were key to Vertex panel recommendation May 13 2015
Vertex Pharmaceuticals' Orkambi Wins FDA Panel Backing - Analyst Blog May 13 2015
Vertex: 'We Remain Confident in Approval,' JPMorgan Says May 13 2015
Vertex Shares Rally As FDA Panel Backs Orkambi; HC Wainwright Analyst Offers Thoughts May 13 2015
Early movers: DAL, PLL, HUM, VZ, KMB, FB & more May 13 2015
FDA Panel Backs Vertex Cystic-Fibrosis Drug Orkambi May 12 2015
Tuesday's After-Hours Movers: Vertex Pharmaceuticals, Orexigen Therapeutics And More May 12 2015
IBD Market Wrap - 05/12/15 May 12 2015
FDA panel approves Vertex drug May 12 2015
FDA panel backs Vertex cystic-fibrosis drug Orkambi May 12 2015
After-hours buzz: American Express, Vertex & more May 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK